As a Money Morning Member, you'll get our top financial news stories delivered straight to your inbox – every weekday morning.
Cancel at any time | How it works
Welcome to Money Morning - Only the News You Can Profit From.
Private Briefingwith WILLIAM PATALON III, Executive Editor
Since launching Private Briefing three years ago, we’ve focused a lot of our attention on the American “Energy Revolution.”
And you’ve cashed in big…
Click here and learn how to get exclusive access to the backdoor way to make a quick 149% before the IPO goes public in September. Don't worry... this play has nothing to do with the "obvious" companies that've been bandied about on the internet. Go here for full details.
Members log in:
Not a member yet? Sign up here or learn more.
Chief Investment Strategist
33-year seasoned market analyst and professional trader with highly accurate track record. Specialty in global markets.
Global Energy Strategist
35-year expert in oil and gas policy, risk assessment, and emerging market economic development.
Capital Wave Strategist
30-year CBOE trader, market maker, and retired hedge fund honcho. Helped launch the Volatility Index in 1993.
20-year commodity guru and portfolio advisor. Top authority on metals + mining stocks. Head- quartered in Canada.
Defense + Tech Specialist
30-year veteran of tech markets with a Rolodex of Silicon Valley CEOs. Pulitzer nominee. Uncovered rare earths crisis.
30-year veteran analyst of business, economics, and financial markets. Award-winning author of "Contrarian Investing."
BioScience Investment Specialist
Gifted researcher with 20 years' experience tracking bioscience and pharma stocks. Master of the FDA approval process.
Small-Cap Investing Specialist
Known for his pioneering research on the seven "sparks" that trigger explosive profits in the small-cap sector.
One sector offering stocks to buy now is an industry that's been prepping for huge product deliveries in 2013.
I'm talking about Big Pharma.
After being pummeled by generic rivals for the past few years, a few big pharmaceutical companies are fighting back with a new wave of blockbuster drugs that will hit the market in 2013.
More than ever, Big Pharma companies need new revenue streams to battle the "patent cliff - replacing fading profits from drugs that spawned generic competition.
Last year alone, the industry suffered from the expiration of patents for such lucrative name-brand drugs as AstraZeneca PLC's (NYSE ADR: AZN) Seroquel, Pfizer Inc.'s (NYSE: PFE) Lipitor and Wyeth's Protonix, which total accounted for nearly $36 billion in U.S. sales in 2011 and 2012.
But help is on the way.
Pharmaceutical firms logged 39 new drug approvals last year - the most since 1996 - and there are signs the trend could continue through 2013, according to Reuters.
Drugmakers are betting that a new wave of medicines for cancer, diabetes and heart disease will shape up as tomorrow's blockbusters.
European drugmakers, for example, have the potential to deliver new drugs with peak annual sales of $64 billion in 2013-2015 while patent losses will be only $12 billion, according to Deutsche Bank AG (NYSE: DB) estimates.
No doubt about it - Big Pharma is taking aim at generics with both barrels.
That could mean fat profits for savvy investors who focus on high-quality companies with strong late-stage pipelines.
Here are three that are loaded for 2013.
Innovations in biological science - or biotech - are evolving at the speed of light.
In fact, leading edge biotech products and breakthroughs are saving thousands of lives every day.
And business is booming for one biotech bellwether ...